ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.102,15
0,75%
S&P 500
5.930,85
1,09%
US Dollar vs BRL
6,086
0,00%
Bitcoin
97.384,56
-0,38%
Brent Oil
72,72
0,00%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Avalo Therapeutics Inc (AVTX)

  7. Avalo Therapeutics Inc (AVTX) Notícias

AVTX

Avalo Therapeutics (AVTX)

Avalo Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AVTX
DataHoraFonteTítuloCódigoCompanhia
05/12/202409:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
14/11/202414:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
12/11/202409:00GlobeNewswire Inc.Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement WarrantsNASDAQ:AVTXAvalo Therapeutics Inc
11/11/202409:00GlobeNewswire Inc.Avalo Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:AVTXAvalo Therapeutics Inc
07/11/202409:20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AVTXAvalo Therapeutics Inc
07/11/202409:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVTXAvalo Therapeutics Inc
07/11/202409:00GlobeNewswire Inc.Avalo Reports Third Quarter 2024 Financial Results and Recent Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
08/10/202408:00GlobeNewswire Inc.Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis SuppurativaNASDAQ:AVTXAvalo Therapeutics Inc
07/10/202421:06Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AVTXAvalo Therapeutics Inc
04/09/202408:00GlobeNewswire Inc.Avalo Announces Participation in September Investor ConferencesNASDAQ:AVTXAvalo Therapeutics Inc
14/08/202418:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
12/08/202408:00GlobeNewswire Inc.Avalo Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
06/08/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AVTXAvalo Therapeutics Inc
05/08/202417:36Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AVTXAvalo Therapeutics Inc
29/07/202417:08Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
16/07/202417:17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
16/07/202408:00GlobeNewswire Inc.Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical OfficerNASDAQ:AVTXAvalo Therapeutics Inc
11/07/202417:12Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
24/06/202417:01GlobeNewswire Inc.Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal OfficerNASDAQ:AVTXAvalo Therapeutics Inc
17/06/202408:30GlobeNewswire Inc.Avalo to Present at the Oppenheimer Novel Targets in Immunology SummitNASDAQ:AVTXAvalo Therapeutics Inc
07/06/202408:01Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AVTXAvalo Therapeutics Inc
06/06/202417:03Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AVTXAvalo Therapeutics Inc
03/06/202408:20Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
13/05/202413:38Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AVTXAvalo Therapeutics Inc
13/05/202408:30GlobeNewswire Inc.Avalo Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
02/04/202408:00GlobeNewswire Inc.Avalo Therapeutics Appoints Biotech Leaders to Board of DirectorsNASDAQ:AVTXAvalo Therapeutics Inc
29/03/202417:01GlobeNewswire Inc.Avalo Reports 2023 Financial Results and Provides Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
27/03/202417:01GlobeNewswire Inc.Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionNASDAQ:AVTXAvalo Therapeutics Inc
14/02/202423:13Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
27/12/202309:00GlobeNewswire Inc.Avalo Therapeutics Announces 1-for-240 Reverse Stock SplitNASDAQ:AVTXAvalo Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AVTX

Seu Histórico Recente

BOV
FICT3
Fictor Alimentos
BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
ENGI11
ENERGISA
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados